GlobeNewswire

With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decision Lirafugratinib achieved a 46.5% ORR, in…

– Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with…

The U.S. biosensors market was estimated to be worth USD 11.0 billion in 2025 and is expected to grow at…

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment…

Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer PHILADELPHIA,…

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional…

Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities   Agreement utilizes BullFrog AI’s end-to-end analytical…

LONDON, March 30, 2026 (GLOBE NEWSWIRE) — Capitalzodiac, a distinguished UK-based leader in industrial data intelligence and advanced geological market…

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE…

Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at…

ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or…

Created in partnership with Bandolier Media, the new entertainment-driven series asks homeowners one simple question: “You cleaned it. But did…

Ask NiceAI turns fragmented feedback and reviews into instant answers and ready-to-execute action plans Reagan Nickl, AskNicely’s Chief AI Evangelist,…

Funding will enable the Company to support expanded development of its lead asset, ISP-001, for the treatment of mucopolysaccharidosis type…

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026 Received clarifying feedback from the FDA on pharmacokinetic (PK) and…